Physician profile
Sylvia Wright
NPI 1578526836
$9,212.62
in general payments reported to CMS, 2019-2025
29 companies · $1,626 in 2025
The $1,626 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,391 · 2020: $481 · 2021: $671 · 2022: $1,666 · 2023: $1,607 · 2024: $1,772 · 2025: $1,626.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,960 · Grant: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,959.64 |
| Grant | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,115.77 | 2019-2025 | Rinvoq, Skyrizi, Botox |
| Allergan, INC. | $1,834.87 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $801.18 | 2019-2025 | |
| Pfizer INC. | $464.59 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $349.29 | 2020-2025 | Dupixent |
| Galderma Laboratories, L.P. | $321.38 | 2019-2025 | Nemluvio, Aklief, Epsolay |
| E.R. Squibb & Sons, L.L.C. | $297.01 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $249.90 | 2019-2025 | |
| Mayne Pharma Commercial LLC | $235.41 | 2019-2025 | |
| Leo Pharma INC. | $231.49 | 2019-2025 | Adbry, Anzupgo |
| Janssen Biotech, INC. | $196.15 | 2019-2025 | Tremfya |
| Dermavant Sciences, INC. | $164.40 | 2022-2024 | Vtama |
| Amgen INC. | $152.51 | 2022-2024 | Otezla, Enbrel |
| Lilly USA, LLC | $139.38 | 2021-2025 | Ebglyss, Taltz, Zepbound |
| Incyte Corporation | $98.78 | 2024-2025 | Opzelura |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $80.28 | 2023-2025 | Zoryve |
| Journey Medical Corporation | $66.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.57 | 2022-2024 | Spevigo, Cyltezo |
| Sun Pharmaceutical Industries INC. | $56.06 | 2023-2024 | Ilumya |
| Merz North America, INC. | $47.70 | 2024-2025 | |
| Organon LLC | $42.58 | 2023-2025 | Vtama, Hadlima |
| Botanix Sb INC | $42.32 | 2025 | Sofdra |
| Almirall LLC | $33.91 | 2019-2022 | |
| Ucb, INC. | $33.04 | 2023-2024 | Bimzelx |
| Sebela Pharmaceuticals INC. | $27.33 | 2019 | |
| Verrica Pharmaceuticals INC. | $22.83 | 2023 | Ycanth |
| Epi Health, LLC | $18.00 | 2022 | |
| Prugen, INC. Pharmaceuticals | $15.54 | 2019 | |
| Solta Medical, A Division of Bausch Health US, LLC | $12.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sylvia Wright listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.